Kintara Therapeutics (KTRA) director List received 27,106 Options (Right to Buy)

Insider transactions reported

Alan List (director at Kintara Therapeutics Inc., KTRA) reported that they received 27,106 Options (Right to Buy) on Oct 18, 2024.

Reporting person

List Alan

Options and other derivatives

Holdings before and after

• Options (Right to Buy): 0 to 13,553 direct

Footnotes from the filing

1. 1. Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the Merger Agreement ), among the Issuer (fka Kintara Therapeutics, Inc. ), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ( Merger Sub ), and TuHURA Biosciences, Inc., a Delaware corporation ( Private TuHURA ). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the Merger ) with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to TuHURA Biosciences, Inc.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ